Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2017091577) FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/091577 International Application No.: PCT/US2016/063332
Publication Date: 01.06.2017 International Filing Date: 22.11.2016
IPC:
C07K 16/28 (2006.01) ,G01N 33/574 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
574
for cancer
Applicants:
FIVE PRIME THERAPEUTICS, INC. [US/US]; 111 Oyster Point Boulevard South San Francisco, California 94080, US
Inventors:
PIERCE, Kristen; US
POWERS, Janine; US
PALENCIA, Servando; US
SIKORSKI, Robert; US
GHODDUSI, Majid; US
KRISHNAN, Kartik; US
Agent:
DOHERTY, Elizabeth A.; US
SCARR, Rebecca B.; US
Priority Data:
62/258,73123.11.2015US
62/314,17428.03.2016US
62/379,09424.08.2016US
Title (EN) FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT
(FR) INHIBITEURS DE FGFR2 SEULS OU EN COMBINAISON AVEC DES AGENTS DE STIMULATION IMMUNITAIRE DANS LE TRAITEMENT DU CANCER
Abstract:
(EN) Provided herein are uses of fibroblast growth factor receptor 2 (FGFR2) inhibitors in cancer treatment, in some cases in combination with immune stimulating agents, such as inhibitors of PD-1 or PD-L1. In some embodiments, FGFR2 inhibitors may comprise FGFR2 antibodies or FGFR2 extracellular domain (ECD) polypeptides, or FGFR2 ECD fusion molecules comprising an FGFR2 ECD and a fusion partner. In some embodiments, PD-1/PD-L1 inhibitors may comprise anti-PD-1 antibodies such as antibodies that bind to PD-1 or to PD-L1 and inhibit interactions between these proteins, as well as PD-1 fusion proteins or polypeptides.
(FR) L'invention concerne des utilisations d’inhibiteurs du récepteur 2 du facteur de croissance fibroblastique (FGFR2) dans le traitement du cancer, dans certains cas en combinaison avec des agents de stimulation immunitaire, tels que des inhibiteurs de PD-1 ou PD-L1. Selon certains modes de réalisation, les inhibiteurs de FGFR2 peuvent comprendre des anticorps de FGFR2 ou des polypeptides de domaines extracellulaire de FGFR2 (ECD), ou des molécules de fusion d'ECD de FGFR2 comprenant un ECD de FGFR2 et un partenaire de fusion. Selon certains modes de réalisation, les inhibiteurs de PD-1/PD-L1 peuvent comprendre des anticorps anti-PD-1 tels que des anticorps se liant à PD-1 ou PD-L1 et inhibent les interactions entre ces protéines, ainsi que des protéines ou des polypeptides de fusion de PD-1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
CA3004794AU2016359609SG11201804134YKR1020180081606CN108368174EP3380523
BR112018010410